Imatinib
Acral Lentiginous Malignant Melanoma
National Cancer Institute (NCI)Small moleculePhase 2Dormant
B
61/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 46/ 100
- Competitive Position
- 95/ 100
Competitive context
19 Active assets in the Acral Lentiginous Malignant Melanoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pembrolizumab Yonsei University | Phase 2 | BB |
Rivoceranib Peking University Cancer Hospital & Institute | Phase 3 | B |
Nivolumab Fred Hutchinson Cancer Center | Phase 2 | B |
Nilotinib Institute of Cancer Research, United Kingdom | Phase 2 | B |
ibi310 Innovent Biologics (Suzhou) Co. Ltd. | Phase 3 | B |
View all 29 →
Same molecule, other indications
Imatinib is also rated in:
blast phase chronic myelogenous leukemia, BCR-ABL1 positiveDormant
BB
Indicative ·
71 / 100
View asset →B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant
BB
Indicative ·
69 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →